leadXpro

Executive Summary

leadXpro, founded in 2015 and based in Villigen, Switzerland, is a private biotechnology company specializing in structure-based drug discovery for membrane proteins. The company has established a robust platform encompassing protein science, biophysics, and structural determination for over 100 drug targets, enabling the development of small molecule therapeutics against challenging membrane protein classes. By leveraging advanced techniques such as X-ray crystallography and cryo-EM, leadXpro aims to accelerate the drug discovery process for its partners and internal programs. Despite limited public information on funding and pipeline specifics, the company's focus on a high-value area of drug discovery positions it as a potential player in the membrane protein space.

Upcoming Catalysts (preview)

• TBDNew pharmaceutical collaboration or licensing deal60% success
• TBDSeries A or B financing round50% success
• Q3 2026Presentation of preclinical data for a lead candidate40% success